When a person is diagnosed with Parkinson’s disease—especially when medication becomes less reliable, involuntary movements develop, or deep brain stimulation is being considered—it is natural for patients and families to look beyond their home country for specialist expertise.
China has a large population of people living with Parkinson’s disease and a number of medical centers with experience in movement disorders, deep brain stimulation, remote device programming, rehabilitation, and early-stage cell therapy research. For some international patients, China may offer access to a second opinion, a structured surgical assessment, or information about registered clinical trials.
However, this does not mean that China can cure Parkinson’s disease. It also does not mean that every new technology being studied in China is available as a treatment that patients can simply purchase.
To understand the real potential of Parkinson’s care in China, it is important to distinguish among three categories:
- Established treatments already used in routine clinical practice;
- New technologies that are still being studied or refined;
- Experimental interventions whose effectiveness has not yet been established.
Key Points
For international patients considering medical care in China, the most realistic potential benefits currently include:
- Obtaining a second opinion from a large movement disorders center;
- Reassessing the diagnosis, medication response, and stage of Parkinson’s disease;
- Determining whether the patient is a suitable candidate for deep brain stimulation;
- Receiving preoperative assessment, surgery, and postoperative programming for deep brain stimulation;
- Reassessing patients who already have a deep brain stimulation device but have not achieved satisfactory results;
- Learning about remote programming and other newer approaches to postoperative management;
- Receiving multidisciplinary assessment involving neurology, neurosurgery, rehabilitation, and medical imaging;
- Finding out whether the patient may meet the eligibility criteria for a registered clinical trial.
The following claims should not currently be presented as proven advantages of seeking Parkinson’s treatment in China:
- Stem cell treatment can already cure or reverse Parkinson’s disease;
- International patients can pay to receive experimental cell therapy directly;
- Patients in Hainan or elsewhere in China can freely choose any unapproved treatment;
- Treatment outcomes in China are necessarily better than those in Europe or North America;
- The total cost of deep brain stimulation in China is always lower than in other countries;
- Joining a clinical trial in China means the patient will definitely receive an effective treatment.
1. One of China’s Main Advantages Is Clinical Volume and Specialist Experience
Parkinson’s disease cannot usually be managed through a single routine consultation.
Long-term care may involve:
- Slowness of movement, tremor, and muscle rigidity;
- Wearing-off effects and “on-off” fluctuations;
- Involuntary movements caused by levodopa;
- Freezing of gait and balance problems;
- Sleep, mood, cognitive, and autonomic symptoms;
- Swallowing and speech difficulties;
- Assessment for deep brain stimulation;
- Long-term postoperative programming and medication adjustment.
One practical advantage in China is that some large medical centers have accumulated substantial experience with Parkinson’s disease and deep brain stimulation.
A nationwide survey covering 74 medical centers examined the use of deep brain stimulation for Parkinson’s disease in China between 1997 and 2021. The study showed that China has developed a sizeable network of centers performing deep brain stimulation, although access remains uneven across different regions.
Another Chinese multicenter cohort study included 1,717 patients with Parkinson’s disease who underwent deep brain stimulation of the subthalamic nucleus. At two years, patients showed improvements in motor symptoms, anxiety, depression, and quality of life. Patients with a disease duration of five to ten years appeared to show particularly favorable overall outcomes.
These studies do not prove that treatment in China is superior to treatment elsewhere. They do, however, show that some Chinese centers have accumulated substantial real-world clinical experience.
For an international patient, this experience may be valuable for:
- A more complete assessment of whether surgery is appropriate;
- Determining which symptoms are realistically likely to improve after deep brain stimulation;
- Avoiding decisions based only on age, disease duration, or a single symptom;
- Receiving a combined opinion from a movement disorders neurologist and a functional neurosurgeon;
- Developing a more structured plan for target selection, device choice, and postoperative programming.
2. Deep Brain Stimulation Is an Established Treatment, but It Is Not Suitable for Everyone
Deep brain stimulation is an established treatment for selected patients with moderate or advanced Parkinson’s disease.
The procedure usually involves implanting electrodes into specific areas of the brain and connecting them to a pulse generator that delivers continuous electrical stimulation.
Deep brain stimulation is mainly used to improve:
- Motor symptoms that still respond to levodopa;
- Significant medication fluctuations;
- Levodopa-induced involuntary movements;
- Certain forms of difficult-to-control tremor.
It does not stop Parkinson’s disease from progressing, and it does not reliably improve every symptom.
For example, severe cognitive impairment, major psychiatric symptoms, some gait and balance problems, and certain non-motor symptoms may limit the benefit of surgery.
For this reason, the most valuable first step for an international patient seeking deep brain stimulation in China is usually not immediate surgery. It is a structured preoperative assessment, which may include:
- Confirming the diagnosis;
- Measuring the response to levodopa;
- Documenting symptoms during medication “on” and “off” periods;
- Assessing cognition and mental health;
- Reviewing brain imaging;
- Discussing the patient’s and family’s expectations;
- Planning how the device will be programmed and maintained after the patient returns home.
For patients living in areas with limited access to movement disorders specialists or functional neurosurgery teams, some large Chinese centers may be able to provide a more concentrated and comprehensive assessment.
3. A Shanghai-Specific Development: Remote Programming Research at Ruijin Hospital
Deep brain stimulation does not end when surgery is completed.
After surgery, patients usually require repeated programming sessions. During these sessions, clinicians adjust factors such as electrical current, voltage, frequency, pulse width, and electrode contact combinations according to symptoms, medication use, and side effects.
Traditional programming requires patients to return repeatedly to the implanting hospital. For people living in another city, a remote area, or another country, this can create substantial travel, time, and caregiving burdens.
China has conducted research on remote programming for deep brain stimulation and published national guidance on remote programming for patients with Parkinson’s disease.
One registered randomized controlled trial, identified as NCT06078397, was initiated and conducted by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The study is designed to compare remote programming with standard in-person programming after deep brain stimulation surgery in people with Parkinson’s disease.
This is particularly relevant for patients considering treatment in Shanghai. It shows that Shanghai is not only performing deep brain stimulation surgery, but is also studying how to improve long-term postoperative management.
A team from Ruijin Hospital has also published a case series describing patients whose postoperative deep brain stimulation programming was managed entirely remotely.
However, international patients should understand an important limitation:
The fact that remote programming is possible within China does not mean that cross-border remote programming will automatically be available after the patient returns home.
Whether cross-border remote programming is possible depends on:
- The brand and model of the implanted device;
- Whether the device supports remote programming;
- Medical device and telemedicine regulations in the patient’s home country;
- The hospital’s policy on cross-border remote care;
- Availability of the required network and software platform;
- Whether a local doctor is available to manage urgent problems;
- How infection, device failure, or other complications would be handled.
Before undergoing deep brain stimulation in China, an international patient should ask the hospital to explain the long-term maintenance plan in detail.
4. China Is Developing More Advanced Neuromodulation Technologies
In addition to conventional continuous stimulation, Chinese research teams are studying:
- Adaptive deep brain stimulation;
- Closed-loop neuromodulation;
- Implantable devices that can record brain signals;
- Systems that adjust stimulation according to symptoms or neural activity;
- Remote motor assessment;
- Home-based levodopa response testing;
- Digital monitoring of symptoms.
A Chinese multicenter study published in 2025 compared adaptive deep brain stimulation with conventional continuous stimulation. Research of this kind shows that China is not only expanding access to deep brain stimulation, but is also working to improve devices and stimulation strategies.
However, adaptive deep brain stimulation and related technologies are still developing. Patients should confirm:
- Whether the device has received formal regulatory approval;
- Whether the intervention is part of routine care or a clinical study;
- Whether the hospital has meaningful practical experience with the technology;
- Whether the technical improvement has translated into a noticeable clinical benefit;
- Whether the device can be maintained in the patient’s home country.
A newer technology is not automatically a better treatment.
5. Cell Therapy Is an Active Area of Research in China, but It Is Not Yet an Established Treatment
A major pathological feature of Parkinson’s disease is the gradual loss of dopamine-producing neurons in the brain.
Researchers have therefore long explored whether dopamine-producing neural precursor cells derived from stem cells can be transplanted to replace lost function.
Shanghai East Hospital and Sizhe Biopharmaceuticals have conducted a clinical study involving the transplantation of dopamine-producing neural precursor cells derived from human induced pluripotent stem cells into the brains of patients with Parkinson’s disease. The study is registered on ClinicalTrials.gov under the identifier NCT06145711.
This shows that some Parkinson’s cell therapy programs in China have moved beyond laboratory research and entered early human clinical testing.
However, international patients need to understand the level of evidence accurately.
Early-stage clinical trials mainly examine:
- Safety;
- Tolerability;
- Feasibility of the procedure;
- Risks of tumor formation, abnormal cell growth, or severe immune reactions;
- Preliminary signals of symptom improvement;
- Whether transplanted cells survive over time.
Such trials do not yet prove that:
- The treatment can cure Parkinson’s disease;
- The treatment can reliably reverse disease progression;
- Every patient will benefit;
- Long-term risks are known;
- International patients can receive the treatment simply by paying for it.
Participation in a clinical trial also requires patients to meet strict eligibility criteria and undergo review by the research team, ethics committee, and informed consent process.
For international patients, the practical meaning of China’s cell therapy research is therefore:
China may offer some eligible patients the opportunity to participate in a formally registered early-stage clinical trial. It does not currently offer a proven commercial stem cell treatment for Parkinson’s disease.
6. A Laboratory Breakthrough Does Not Mean a Treatment Is Available to Patients
Chinese researchers are also studying nanomedicine, gene therapy, and new forms of neuromodulation.
For example, a study published in Science Advances used a system combining gold nanoparticles, antibodies, and peptides to improve movement and Parkinson’s-related changes in a mouse model.
This is scientifically important preclinical research, but the subjects were mice, not human patients.
Such findings are sometimes simplified into claims such as:
China has already reversed Parkinson’s disease using nanoparticles.
That statement is inaccurate.
Moving from an animal experiment to routine patient treatment usually requires:
- Independent replication;
- Toxicology and biocompatibility studies;
- Determination of appropriate human dosing;
- Early safety trials;
- Multiple stages of human clinical trials;
- Regulatory approval;
- Long-term follow-up.
International patients should not arrange treatment in China based only on laboratory research news. They should also avoid paying for an experimental intervention if the provider cannot show a registered clinical trial, ethics approval, and a formal study protocol.
7. China Has an Active Clinical Research Environment, but Trial Access Is Not a Treatment Guarantee
A Parkinson’s disease clinical trial landscape report published by Novotech stated that more than 750 industry-sponsored Parkinson’s clinical trials had been initiated globally since 2019. The Asia-Pacific region is an important research area, and mainland China is one of its major contributors.
This suggests that China has a relatively active research environment.
However, an active research environment does not mean:
- Most of the 750 trials were conducted in China;
- Every trial accepts international patients;
- Patients can choose any trial themselves;
- Enrollment guarantees access to the experimental treatment;
- The experimental treatment is effective;
- All costs are covered by the study.
Some trials may include a placebo group, a control group, or random allocation. Some studies collect only imaging, blood samples, or symptom data. Some trials may be limited to Chinese residents or require long-term follow-up in China.
Before considering a clinical trial, an international patient should confirm:
- Whether the study is registered on a reliable clinical trial platform;
- Whether the study is actively recruiting;
- Which hospital and investigator are responsible;
- Whether international patients are eligible;
- What the inclusion and exclusion criteria are;
- Whether treatment is assigned randomly;
- Which costs are covered by the study;
- Who is responsible for managing adverse events;
- How long the patient must remain in China;
- How long-term follow-up will be completed after the patient returns home.
8. The Main Benefit of Seeking Care in China May Not Be Access to the Newest Experimental Therapy
For most patients with Parkinson’s disease, the most realistic value of seeking care in China is more likely to come from established medical expertise than from high-risk experimental interventions.
8.1 Specialist Second Opinion
A specialist team may help reassess:
- Whether the diagnosis is truly Parkinson’s disease;
- Whether the patient may have an atypical Parkinsonian syndrome;
- Whether the medication regimen is appropriate;
- Whether symptom fluctuations can be managed more effectively;
- Whether it is time to consider deep brain stimulation.
8.2 Preoperative Assessment for Deep Brain Stimulation
An experienced center can evaluate medication response, motor symptoms, cognition, mood, imaging, and quality of life together, rather than recommending surgery simply because medication is becoming less effective.
8.3 Reassessment After Deep Brain Stimulation
If a patient has had surgery but is not doing well, possible explanations include:
- The patient was not an ideal candidate;
- The electrode position is suboptimal;
- The programming parameters are not well adjusted;
- Medication and stimulation settings are not well coordinated;
- The patient’s symptoms are not highly responsive to deep brain stimulation;
- The disease has progressed.
Not every patient requires another operation. In some cases, improved programming and medication adjustment may help.
8.4 Concentrated Multidisciplinary Assessment
Some large hospitals can arrange neurology, neurosurgery, rehabilitation, imaging, cognitive, and swallowing assessments within a relatively short period.
For patients living in regions with limited specialist resources, this concentrated approach may offer practical value.
8.5 Understanding Registered Clinical Research
Research centers may help patients understand how mature a new technology really is, whether they may qualify for a clinical trial, and how to distinguish scientific evidence from commercial promotion.
9. Costs May Be Competitive, but Lower Total Cost Cannot Be Guaranteed
Outpatient consultations, imaging, hospital stays, and surgery at some Chinese public hospitals may cost less than self-funded care in parts of Europe or North America.
However, the true total cost of Parkinson’s care may include:
- Specialist consultations;
- Laboratory testing and imaging;
- The deep brain stimulation device and surgical materials;
- Surgery;
- Hospital admission;
- Medication;
- Repeated programming sessions;
- Rehabilitation;
- Translation and patient escort services;
- Travel and accommodation;
- Device maintenance after returning home;
- Management of complications;
- Whether insurance provides reimbursement.
There is currently not enough standardized and reliable international comparison data to conclude that comprehensive Parkinson’s treatment in China is always cheaper for an international patient.
A more accurate statement is:
Medical services at some Chinese public hospitals may be competitively priced, but patients should compare formal quotations for equivalent services before making a decision.
10. Which International Patients May Benefit Most?
Patients Who May Reasonably Consider Care in China
- Patients seeking a second opinion on their diagnosis or treatment plan;
- Patients living in areas with limited access to movement disorders specialists;
- Patients considering deep brain stimulation who want a structured preoperative assessment;
- Patients who already have a deep brain stimulation device but are not satisfied with programming results;
- Patients who want to understand remote programming or newer neuromodulation technologies;
- Patients who want to find out whether they may qualify for a registered clinical trial;
- Patients who can complete the necessary assessment and follow-up in China;
- Patients who will continue to have medical follow-up after returning home.
Patients Who Should Be Especially Cautious
- Patients expecting a single treatment to cure Parkinson’s disease;
- Patients preparing to purchase stem cell therapy based on online advertising;
- Patients whose condition is unstable and who may not be fit for long-distance travel;
- Patients unable to complete long-term follow-up;
- Patients who do not fully understand the risks of surgery or experimental treatment;
- Patients without a clear plan for care and device maintenance after returning home;
- Patients who are promised “guaranteed reversal,” “guaranteed effectiveness,” or treatment without formal regulatory oversight.
11. What Should Be Confirmed Before Traveling to China?
Before booking flights, an international patient should confirm:
- The official name of the hospital and department;
- Whether the doctor actually practices at that institution;
- Whether the appointment has been confirmed;
- Which hospital campus the patient should attend;
- Whether the service is a routine outpatient visit, an international medical service, or a clinical trial;
- Whether a Chinese medical summary is required;
- How long the patient is expected to remain in China;
- Whether the hospital can provide a formal cost estimate;
- Whether professional medical interpretation is required;
- Whether the deep brain stimulation device can be maintained in the patient’s home country;
- Whether cross-border remote programming is possible;
- Whether a clinical trial accepts international participants;
- Whether the experimental intervention involves any patient charges;
- Who will manage complications;
- How care will be transferred back to the patient’s local doctor.
Only with this level of transparency can the potential of medical travel to China be based on genuine medical capability rather than on hope or unverified promises.
References
- World Health Organization. Parkinson disease. WHO Fact Sheets. Published August 9, 2023.
- Wang S, Hu W, Gao Y, et al. Deep brain stimulation surgical timing, outcomes, and prognostic factors in patients with Parkinson’s disease: a Chinese retrospective multicenter cohort study. PLoS Medicine. 2025;22(8):e1004670. doi:10.1371/journal.pmed.1004670.
- Meng F, Hu W, Wang S, et al. Utilization, surgical populations, centers, coverages, regional balance, and their influential factors of deep brain stimulation for Parkinson’s disease: a large-scale multicenter cross-sectional study from 1997 to 2021. International Journal of Surgery. 2023;109(11):3322–3336. doi:10.1097/JS9.0000000000000603.
- Zhang Y, Li D, Zhang C, et al. Quality of life and motor outcomes in patients with Parkinson disease after deep brain stimulation: a prospective multicenter study. Neuromodulation. 2023;26:974–983. PMID:36411150.
- Meng F, Zhang J, Zhang W, et al. Chinese guidelines on remote programming of deep brain stimulation for patients with Parkinson’s disease. Chinese Medical Journal. 2025;138(3):261–263. doi:10.1097/CM9.0000000000003390.
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Remote Programming for Deep Brain Stimulation in Parkinson’s Disease. ClinicalTrials.gov identifier: NCT06078397.
- Wan X, Lin Z, Duan C, Zeng Z, Zhang C, Li D. Towards full remote programming for deep brain stimulation in Parkinson’s disease: a case series. Digital Health. 2024;10:20552076241287071. doi:10.1177/20552076241287071.
- Wan X, Lin Z, Duan C, Zeng Z, Zhang C, Li D. Comparison of the burdens and attitudes between standard and web-based remote programming for deep brain stimulation in Parkinson disease: survey study. JMIR Aging. 2024;7:e57503. doi:10.2196/57503.
- Li Q, Wang K, Wei P, et al. Adaptive versus conventional deep brain stimulation of the subthalamic nucleus for treatment of Parkinson’s disease: a multicenter retrospective study. Neuromodulation. 2025. doi:10.1016/j.neurom.2025.04.011.
- Shanghai East Hospital; Sizhe Biopharmaceuticals. A clinical trial of Parkinson’s disease treatment by human induced pluripotent stem cell-derived dopaminergic progenitor cells. ClinicalTrials.gov identifier: NCT06145711.
- Wu J, et al. A nanoparticle-based wireless deep brain stimulation system that reverses Parkinson’s disease. Science Advances. 2025;11(3):eado4927. doi:10.1126/sciadv.ado4927.
- Novotech. Parkinson’s Disease: Global Clinical Trial Landscape 2024. Novotech Clinical Research Organization; 2024.
- Chu J, Wu L, Jiang L, et al. Long-term efficacy of deep brain stimulation in Parkinson’s disease: over 10-year follow-up and insights into the “deep brain stimulation honeymoon.” Therapeutic Advances in Neurological Disorders. 2025. doi:10.1177/17562864251388840.